Minocycline as an adjunct for treatment-resistant depressive symptoms: study protocol for a pilot randomised controlled trial

Muhammad I Husain, Imran B Chaudhry, Raza R Rahman, Munir M Hamirani, Inti Qurashi, Ameer B Khoso, John F W Deakin, Nusrat Husain, Allan H Young, Muhammad I Husain, Imran B Chaudhry, Raza R Rahman, Munir M Hamirani, Inti Qurashi, Ameer B Khoso, John F W Deakin, Nusrat Husain, Allan H Young

Abstract

Background: Depression is one of the leading causes of disability worldwide. A high proportion of patients do not respond to standard drug treatments. Recent evidence has suggested that anti-inflammatory treatment may have beneficial effects in major depression. Minocycline is a tetracycline antibiotic with good CNS penetration that exerts effects on multiple interacting symptoms implicated in the pathophysiology of mood disorders. Open-label studies have suggested that minocycline is effective as an adjunct drug in improving depressive symptoms.

Methods/design: This is a multi-centre, 3-month, double-blind, placebo-controlled, pilot trial of minocycline added to treatment as usual for patients suffering from DSM-IV major depressive disorder. This will be a double-blind, randomised, controlled, two parallel-arm study with 20 participants in each arm, giving a total of 40 participants. There will be a screening visit, a randomization visit and four follow-up visits. Clinical assessments using the Hamilton Depression Rating Scale (HAM-D), Clinical Global Impression scale (CGI), Patient Health Questionnaire-9 (PHQ -9) and the Generalised Anxiety Disorder scale (GAD-7) will be carried out at every visit. Side effects checklists will also be undertaken at each visit. Biomarkers (inflammatory cytokines and CRP) will be measured at baseline and at the end of the treatment phase. Minocycline will be started at 100 mg once daily (OD) and will be increased to 200 mg at two weeks.

Discussion: Anti-inflammatory treatments have been shown to have some beneficial effects in the treatment of major depressive disorder. The aim of this pilot randomised controlled trial is to establish the degree of improvement in depressive symptoms with the addition of minocycline to treatment as usual.

Trial registration: ClinicalTrials.gov NCT02263872 registered 10 October 2014.

References

    1. World Health Organization . The Global Burden of Disease. Geneva: WHO Press; 2012.
    1. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163:1905–17. doi: 10.1176/appi.ajp.163.11.1905.
    1. Linde K, Kriston L, Rücker G, Jamil S, Schumann I, Meissner K, et al. Efficacy and Acceptability of Pharmacological Treatments for Depressive Disorders in Primary Care: Systematic Review and Network Meta-Analysis. Ann Fam Med. 2015;13:69–79. doi: 10.1370/afm.1687.
    1. O'Donovan A, Rush G, Hoatam G, Hughes BM, McCrohan A, Kelleher C, et al. Suicidal ideation is associated with elevated inflammation in patients with major depressive disorder. Depress Anxiety. 2013;30:307–14. doi: 10.1002/da.22087.
    1. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008;9:46–56. doi: 10.1038/nrn2297.
    1. Song C, Dinan T, Leonard BE. Changes in immunoglobulin, complement and acute phase protein levels in the depressed patients and normal controls. J Affect Disord. 1994;30:283–8. doi: 10.1016/0165-0327(94)90135-X.
    1. Mardini HE, Kip KE, Wilson JW. Crohn's disease: a two-year prospective study of the association between psychological distress and disease activity. Dig Dis Sci. 2004;49:492–7. doi: 10.1023/B:.
    1. Van Gool AR, Kruit WH, Engels FK, Stoter G, Bannink M, Eggermont AM. Neuropsychiatric side effects of interferon-alfa therapy. Pharm World Sci. 2003;25:11–20. doi: 10.1023/A:1022449613907.
    1. Capuron L, Miller AH. Immune system to brain signaling: neuropsychopharmacological implications. Pharmacol Ther. 2011;130:226–38. doi: 10.1016/j.pharmthera.2011.01.014.
    1. Muller N, Schwarz MJ, Dehning S, Douhe A, Cerovecki A, Goldstein-Muller B, et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry. 2006;11:680–4. doi: 10.1038/sj.mp.4001805.
    1. Faridhosseini F, Sadeghi R, Farid L, Pourgholami M. Celecoxib: a new augmentation strategy for depressive mood episodes. A systematic review and meta-analysis of randomized placebo-controlled trials. Hum Psychopharmacol. 2014;29:216–23. doi: 10.1002/hup.2401.
    1. Warner-Schmidt JL, Vanover KE, Chen EY, Marshall JJ, Greengard P. Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by anti-inflammatory drugs in mice and humans. Proc Natl Acad Sci U S A. 2011;108:9262–7. doi: 10.1073/pnas.1104836108.
    1. Soczynska JK, Mansur RB, Brietzke E, Swardfager W, Kennedy SH, Woldeyohannes HO, et al. Novel therapeutic targets in depression: Minocycline as a candidate treatment. Behav Brain Res. 2012;235:302–17. doi: 10.1016/j.bbr.2012.07.026.
    1. Chaudhry IB, Hallak J, Husain N, Minhas F, Stirling J, Richardson P, et al. Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment. J Psychopharmacol. 2012;26:1185. doi: 10.1177/0269881112444941.
    1. Miyaoka T, Wake R, Furuya M, Liaury K, Ieda M, Kawakami K, et al. Minocycline as adjunctive therapy for patients with unipolar psychotic depression: an open-label study. Prog Neuropsychopharmacol Biol Psychiatry. 2012;37:222–6. doi: 10.1016/j.pnpbp.2012.02.002.
    1. US Food and Drug Administration: Drug Study Design Information Sheet. . Access date 08/09/2015.
    1. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiat. 1960;23:56–62. doi: 10.1136/jnnp.23.1.56.
    1. Faries D, Herrera J, Rayamajhi J, DeBrota D, Demitrack M, Potter WZ. The responsiveness of the Hamilton Depression Rating Scale. J Psychiatr Res. 2000;34:3–10. doi: 10.1016/S0022-3956(99)00037-0.
    1. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavas J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998; 59 Suppl 20:22–33. quiz 34–57.
    1. Nisar N, Billoo N, Gadit AA. Prevalence of depression and the associated risks factors among adult women in a fishing community. J Pak Med Assoc. 2004;54:519–25.
    1. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16:606–13. doi: 10.1046/j.1525-1497.2001.016009606.x.
    1. Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166:1092–7. doi: 10.1001/archinte.166.10.1092.
    1. Chaudhry IB, Husain N, Khan S, Badshah S, Deakin B, Kapur S. Amoxapine as an antipsychotic: comparative study versus haloperidol. J Clin Psychopharmacol. 2007;27:575–81. doi: 10.1097/jcp.0b013e31815a4424.
    1. Hirschfeld RMA, Williams JB, Spitzer RL, Calabrese JR, Flynn L, Keck PE, Jr, et al. Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire. Am J Psychiatry. 2000;157:1873–5. doi: 10.1176/appi.ajp.157.11.1873.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel